Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Completed Initiated Aug 9, 2023 (3 years ago)

Unguentine Ointment

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Unguentine Ointment, (Camphor 3.0%, Phenol 2.5%, Tannic Acid 2.2%, Zinc Oxide 6.6%), labeled as a) NET WT 1 OZ (28 g) tubes, Improved Formula, UPC 0 11169 10216 0, and b) NET WT 1 OZ (28.3g) tubes, Maximum Strength, UPC 0 11169 11250 3, Distributed by: Oakhurst Company, Levittown, NY 11756.

Drug: Zinc

Recalling firm
Ecometics, Inc.
Origin
CT, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1099-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now completed, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Zinc recalls

See all
Class II · Moderate risk

Zicam

CGMP Deviations; FDA inspection of the contract manufacturer noted out of limit results for microbiological testing

Ongoing Microbial contamination Church & Dwight Co., Inc. D-0790-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0642-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0641-2026
Class II · Moderate risk

Med Pride

CGMP Deviations; deficiencies observed during FDA inspection

Ongoing cGMP deviation Dabur India Limited D-0637-2026

Other recalls by Ecometics, Inc.

All 2023 recalls
Class II · Moderate risk

AstrinGyn (Ferric Subsulfate)

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. NDC 59365-6065-0 D-1101-2023
Class II · Moderate risk

activator concentrate

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1100-2023
Class II · Moderate risk

Alcolado Relampago

CGMP Deviations: Products not manufactured under current good manufacturing practices.

Completed cGMP deviation Ecometics, Inc. D-1098-2023